Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Fulminant type 1 diabetes mellitus associated with pembrolizumab.

× No keyword cloud information.

7 in total

Review 1. Is immune checkpoint inhibitor-associated diabetes the same as fulminant type 1 diabetes mellitus?

Authors: Angelos Kyriacou; Eka Melson; Wentin Chen; Punith Kempegowda
Journal: Clin Med (Lond) Date: 2020-07 Impact factor: 2.659

Review 2. Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints.

Authors: Lee-Shing Chang; Romualdo Barroso-Sousa; Sara M Tolaney; F Stephen Hodi; Ursula B Kaiser; Le Min
Journal: Endocr Rev Date: 2019-02-01 Impact factor: 19.871

Review 3. Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports.

Authors: Meng H Tan; Ravi Iyengar; Kara Mizokami-Stout; Sarah Yentz; Mark P MacEachern; Li Yan Shen; Bruce Redman; Roma Gianchandani
Journal: Clin Diabetes Endocrinol Date: 2019-01-22

4. New-onset insulin-dependent diabetes due to nivolumab.

Authors: Ali A Zaied; Halis K Akturk; Richard W Joseph; Augustine S Lee
Journal: Endocrinol Diabetes Metab Case Rep Date: 2018-03-28

Review 5. Immunotherapy-induced endocrinopathies: assessment, management and monitoring.

Authors: Edson Nogueira; Tom Newsom-Davis; Daniel L Morganstein
Journal: Ther Adv Endocrinol Metab Date: 2019-12-25 Impact factor: 3.565

Review 6. Endocrine toxicity of cancer immunotherapy: clinical challenges.

Authors: Bliss Anderson; Daniel L Morganstein
Journal: Endocr Connect Date: 2021-03 Impact factor: 3.335

7. Immunotherapy-Associated Pancreatic Adverse Events: Current Understanding of Their Mechanism, Diagnosis, and Management.

Authors: Ya Liu; Hao Zhang; Li Zhou; Weichun Li; Le Yang; Wen Li; Kezhou Li; Xubao Liu
Journal: Front Oncol Date: 2021-02-25 Impact factor: 6.244

7 in total